# EDGAR Filing Document

**Accession Number:** 0001868734
**File Stem:** 0001193125-23-060624
**Filing Date:** 2023-3
**Character Count:** 2752
**Document Hash:** f77fae4a59075b1eb5c6a35543620150
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-23-060624.hdr.sgml**: 20230306

**ACCESSION NUMBER**: 0001193125-23-060624

**CONFORMED SUBMISSION TYPE**: 15-12G

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20230306

**DATE AS OF CHANGE**: 20230306

**EFFECTIVENESS DATE**: 20230306

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** CinCor Pharma, Inc.
- **CENTRAL INDEX KEY:** 0001868734
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 15-12G
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-41201
- **FILM NUMBER:** 23707456

**BUSINESS ADDRESS:**
- **STREET 1:** 230 THIRD AVE., 6TH FLOOR
- **CITY:** WALTHAM
- **STATE:** MA
- **ZIP:** 02451
- **BUSINESS PHONE:** 8445311834

**MAIL ADDRESS:**
- **STREET 1:** 230 THIRD AVE., 6TH FLOOR
- **CITY:** WALTHAM
- **STATE:** MA
- **ZIP:** 02451

------

------

**UNITED STATES** 

**SECURITIES AND EXCHANGE COMMISSION** 

**Washington, D.C. 20549** 

------

**FORM 15** 

------

**CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION** 

**UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934** 

**OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d)** 

**OF THE SECURITIES EXCHANGE ACT OF 1934.** 

**Commission File No. 001-41201** 

------

## CinCor Pharma, Inc.
**(Exact name of registrant as specified in its charter)** 

------

**230 Third Avenue, 6th Floor** 

**Waltham, MA 02451** 

**(844) 531-1834** 

**(Address, including zip code, and telephone number, including area code, of registrant's principal executive offices)** 

**Common Stock, par value $0.00001 per share** 

**(Title of each class of securities covered by this Form)** 

**None** 

**(Titles of all other classes of securities for which a duty to file reports under Section 13(a) or 15(d) remains)** 

------

Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:

---

| | |
|:---|:---|
| Rule 12g-4(a)(1) | ☒ |
| Rule 12g-4(a)(2) | ☐ |
| Rule 12h-3(b)(1)(i) | ☒ |
| Rule 12h-3(b)(1)(ii) | ☐ |
| Rule 15d-6 | ☐ |
| Rule 15d-22(b) | ☐ |

---

Approximate number of holders of record as of the certification or notice date: One.

Pursuant to the requirements of the Securities Exchange Act of 1934, CinCor Pharma, Inc. has caused this certification/notice to be signed on its behalf by the undersigned duly authorized person.

------

---

| | | |
|:---|:---|:---|
|  | **CINCOR PHARMA, INC.** | **CINCOR PHARMA, INC.** |
|  | By: | /s/ David E. White |
|  | Name: | David E. White |
|  | Title: | President |
| Date: March 6, 2023 |  |  |

---